Gabby is a licensed clinical psychologist. She is currently a National Institute on Drug Abuse T32 Research Fellow in Substance Use Disorders Treatment and Services Research at UCSF within the Psychedelics Divisions of Neuroscape. Her research explores transdiagnostic psychological mechanisms (e.g., emotion regulation, metacognition, self-transcendence) underlying the therapeutic outcomes in treatments of mood, anxiety and substance use disorders. She also conducts qualitative research on psychotherapy-related change processes. She has over 11 years of experience working as a therapist and investigator on FDA-approved clinical trials with psilocybin at New York University, Yale and UC San Francisco (UCSF). Her research applies quantitative and qualitative methodologies to study the role of emotion regulation and metacognitive processes (e.g., mindfulness/self-compassion and reappraisal) targeted by psychedelic-assisted therapies for the treatment of addiction, existential distress, and PTSD. Her 2020 study, which found that psilocybin-assisted therapy was associated with improvements 4.5 years after treatment, garnered media attention in several global news outlets including Time, Newsweek, and CNN.